Application of the Phage Lysin Ply5218 in the Treatment of Streptococcus suis Infection in Piglets

Wang, Zhaofei; Ma, Jingjiao; Wang, Jian; Yang, Deok‐Chun; Kong, Licheng; Fu, Qiang; Cheng, Yuqiang; Wang, Hengan; Yan, Yaxian; Sun, Jianhe

doi:10.3390/v11080715

Cited by 10 publications

(4 citation statements)

References 40 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the ECM of biofilms contains phage receptors that compete with those located at the bacterial cell surface. To overcome these limitations of phage therapy, phage-produced enzymes, required for membrane destabilization and bacterial lysis, have been proposed to treat S. suis infections [ 230 , 231 ]. Positive results of this approach have been shown in experimental infections of laboratory animals.…”

Section: Discussionmentioning

confidence: 99%

How Streptococcus suis escapes antibiotic treatments

Uruén

Garcia

Fraile

et al. 2022

Vet Res

View full text Add to dashboard Cite

Streptococcus suis is a zoonotic agent that causes sepsis and meningitis in pigs and humans. S. suis infections are responsible for large economic losses in pig production. The lack of effective vaccines to prevent the disease has promoted the extensive use of antibiotics worldwide. This has been followed by the emergence of resistance against different classes of antibiotics. The rates of resistance to tetracyclines, lincosamides, and macrolides are extremely high, and resistance has spread worldwide. The genetic origin of S. suis resistance is multiple and includes the production of target-modifying and antibiotic-inactivating enzymes and mutations in antibiotic targets. S. suis genomes contain traits of horizontal gene transfer. Many mobile genetic elements carry a variety of genes that confer resistance to antibiotics as well as genes for autonomous DNA transfer and, thus, S. suis can rapidly acquire multiresistance. In addition, S. suis forms microcolonies on host tissues, which are associations of microorganisms that generate tolerance to antibiotics through a variety of mechanisms and favor the exchange of genetic material. Thus, alternatives to currently used antibiotics are highly demanded. A deep understanding of the mechanisms by which S. suis becomes resistant or tolerant to antibiotics may help to develop novel molecules or combinations of antimicrobials to fight these infections. Meanwhile, phage therapy and vaccination are promising alternative strategies, which could alleviate disease pressure and, thereby, antibiotic use.

show abstract

Section: Discussionmentioning

confidence: 99%

How Streptococcus suis escapes antibiotic treatments

Uruén

Garcia

Fraile

et al. 2022

Vet Res

View full text Add to dashboard Cite

show abstract

“…They displayed efficient lytic activity both in in vitro and in vivo (mouse) models against multiple serotypes of S. suis [70,71]. The lysin from phage phi5218, which was the most effective in vitro and in the mouse model, was then tested in vivo in piglets, demonstrating the therapeutic potential in controlling different serotypes of S. suis [72].…”

Section: Pigsmentioning

confidence: 99%

Bacteriophage Therapy in Companion and Farm Animals

Bianchessi,

De Bernardi,

Vigorelli

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Bacteriophages, which are viruses with restricted tropism for bacteria, have been employed for over a century as antimicrobial agents; they have been largely abandoned in Western countries but are constantly used in Eastern European countries with the advent of antibiotics. In recent decades, the growing spread of multidrug-resistant bacteria, which pose a serious threat to worldwide public health, imposed an urgent demand for alternative therapeutic approaches to antibiotics in animal and human fields. Based on this requirement, numerous studies have been published on developing and testing bacteriophage-based therapy. Overall, the literature largely supports the potential of this perspective but also highlights the need for additional research as the current standards are inadequate to receive approval from regulatory authorities. This review aims to update and critically revise the current knowledge on the application of bacteriophages to treat bacterial-derived infectious diseases in animals in order to provide topical perspectives and innovative advances.

show abstract

“…Additionally, phage KAZ14 lysed chicken strains of cephalosporins-resistant and ESBL-producing E. coli strains (Ahmad et al, 2015) and Angelopoulou et al (2019) recommended using phage endolysins to target bovine mastitis pathogens as this treatment option was effective. In the swine industry, where Streptococcus suis is a pathogen of concern, the lysins, Ply5218 and Ply30, were shown to exhibit strong antibacterial activity against this zoonotic pathogen (Tang et al, 2015;Wang, Ma et al, 2019). Commercial phage products applicable in aviculture are being registered in Ukraine and the United States and successful phage treatment outcomes have also resulted in commercial phage product being reviewed by the European Commission for application in agriculture (Górski et al, 2020).…”

Section: Controlling Pathogens In Animal Husbandrymentioning

confidence: 99%

Phages and their lysins: Toolkits in the battle against foodborne pathogens in the postantibiotic era

Huang

Zhang

Tong

et al. 2021

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

Worldwide, foods waste caused by putrefactive organisms and diseases caused by foodborne pathogens persist as public health problems even with a plethora of modern antimicrobials. Our over reliance on antimicrobials use in agriculture, medicine, and other fields will lead to a postantibiotic era where bacterial genotypic resistance, phenotypic adaptation, and other bacterial evolutionary strategies cause antimicrobial resistance (AMR). This AMR is evidenced by the emergence of multiple drug‐resistant (MDR) bacteria and pan‐resistant (PDR) bacteria, which produces cross‐contamination in multiple fields and poses a more serious threat to food safety. A “red queen premise” surmises that the coevolution of phages and bacteria results in an evolutionary arms race that compels phages to adapt and survive bacterial antiphage strategies. Phages and their lysins are therefore useful toolkits in the design of novel antimicrobials in food protection and foodborne pathogens control, and the modality of using phages as a targeted vector against foodborne pathogens is gaining momentum based on many encouraging research outcomes. In this review, we discuss the rationale of using phages and their lysins as weapons against spoilage organisms and foodborne pathogens, and outline the targeted conquest or dodge mechanism of phages and the development of novel phage prospects. We also highlight the implementation of phages and their lysins to control foodborne pathogens in a farm–table–hospital domain in the postantibiotic era.

show abstract

Application of the Phage Lysin Ply5218 in the Treatment of Streptococcus suis Infection in Piglets

Cited by 10 publications

References 40 publications

How Streptococcus suis escapes antibiotic treatments

How Streptococcus suis escapes antibiotic treatments

Bacteriophage Therapy in Companion and Farm Animals

Phages and their lysins: Toolkits in the battle against foodborne pathogens in the postantibiotic era

Contact Info

Product

Resources

About